“Bimekizumab Clinical Efficacy Responses Translate into Improvements in Patient Outcomes to Week 48 in Patients With Moderate to Severe Hidradenitis Suppurativa: Results from BE HEARD I&II”. 2025. SKIN The Journal of Cutaneous Medicine 9 (6): s707. https://doi.org/10.25251/fpf9fe87.